ANDA 76881, held by Strides Pharma. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 76881 (Sertraline Hydrochloride), held by Strides Pharma, was first approved by FDA on Feb 6, 2007, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2007 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Jan 13, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 30, 2015 | Supplement 3Labeling | Approved | None posted |
| Jun 30, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 14, 2008 | Supplement 5Labeling | Approved | None posted |
| Jan 2, 2008 | Supplement 4Labeling | Approved | None posted |
| Feb 6, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters